Graham Doyle

Graham Doyle

Graham Doyle is an Executive Director and Head of European MedTech in the Equity Research department at UBS in London.13 He has over 10 years of experience as a healthcare equity research analyst covering European pharmaceutical, medical technology, and healthcare services companies.1

Professional Experience

• Executive Director, Equity Research at UBS (October 2021 - Present)1
• Healthcare Equity Research Analyst at Liberum (September 2016 - October 2021)1
• Healthcare Equity Research Analyst at Berenberg (July 2013 - September 2016)1
• Healthcare Equity Research Analyst at Liberum (August 2011 - July 2013)1

Education

• Bachelor of Arts (B.A.), Economics, 1.1 from Trinity College, Dublin (2007 - 2011)1

Stock Coverage and Performance

As an analyst at UBS, Graham Doyle currently covers 16 stocks across the healthcare sector with a 51% success rate and an average return of -6.6%.3 Some of his recent notable ratings include:

• Alcon (ALC): Buy rating with a $102.68 price target (July 2024)4
• Koninklijke Philips (PHG): Neutral rating (April 2024)2
• GE HealthCare Technologies (GEHC): Neutral rating with an $88 price target (February 2024)2